Skip to main content
OpenTrials
Completed

NCT Number: NCT05815511

Clinical Trial to Evaluate the Effect of a Probiotic Mixture on the Rosacea Evolution

The clinical trial has a randomized, double-blind, placebo-controlled design, in which the aim is to evaluate the effect of a probiotic mix, with a 12-week treatment, on the evolution of rosacea.

This 12 weeks of treatment are structured into three visits: Visit 1 (initial; week 0), Visit 2 (intermediate; week 6) and Visit 3 (final; week 12).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rosacea Rosacea Papular Type Rosacea, Papulopustular Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Eguren Dermatology and Aesthetics Clinic, Madrid, Spain

Loading trial locations.

About this study

The three visits that make up the study and the actions to be carried out in each of them are described below:

Visit 1 (initial; week 0)

Once the informed consent is signed, a doctor trained for the study performs the initial interview where it is verified that the patient meets all the inclusion criteria and none of the exclusion criteria and their medical history.The investigator will proceed to assign the patient the next study participant number and, according to a previously prepared randomization list, the treatment that they will receive during the study will be assigned.

The investigator will assess the severity and symptoms of rosacea according to the Investigator's Global Assessment (IGA) and Clinician Erythema Assessment (CEA) scales. The patient will also complete a questionnaire to assess the impact on quality of life due to the disease: Dermatology Life Quality Index (DLQI).

Visit 2 (intermediate; week 6)

In this intermediate visit, in addition to assessing the symptoms of the disease with the detailed scales, the investigator will record the adverse events reported by the patient, as well as the concomitant treatments used.

Also, the treatment compliance rate will be calculated by counting the capsules returned by the patient.

Visit 3 (final; week 12)

In the final visit, the same actions will be carried out as in the intermediate visit, evaluating the severity of the disease and the remaining capsules will be collected, to calculate treatment compliance, concomitant treatments and adverse events.

Visit 4 (post-treatment follow-up; week 24)

During this visit, the symptoms of the disease will be assessed with the two scales used in the study and the treatments that the patient has required during the 12 weeks after the end of the study treatment will be counted.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of both sexes of an age equal to or greater than 18 years.
  • Patients diagnosed with papulopustular rosacea with a minimum score of 2 points according to the Investigator's Global Assessment (IGA) index.
  • Signature of informed consent by the patient

Exclusion criteria

  • Pregnant, lactating, and/or women who do not agree to use an effective contraceptive method during the development of the study.
  • Allergy and/or intolerance to any of the components of the product under study.
  • Consumption of antibiotics in the previous two weeks.
  • Consumption of probiotics in the previous two months.
  • Isotretinoin use in the previous six months.
  • Light procedures (IPL, laser, Kleresca) in the previous three months.
  • Participation in other clinical studies in the previous two months.
  • Other dermatological pathologies.

Treatment and study plan

Probiotic mixture

Dietary Supplement

Oral capsule consumption once a day for 12 weeks

Placebo

Dietary Supplement

Oral capsule consumption once a day for 12 weeks

Primary outcomes

  1. Number and percentage of cases responding to the treatment according to the Investigator's Global Assessment (IGA) index score, comparing the baseline with the visits at 6 and 12 weeks

    Time frame: 12 weeks

    IGA index measures the severity of rosacea

    Score range is from 0 to 6 according to the severity of the disease

    0=clear; 1=minimum; 2=mild; 3=mild-moderate; 4=moderate; 5=moderate-severe; 6=severe

    It will be considered a treatment response in IGA scale when the participant improves by at least 2 categories in this index and the final score is 0-1 points (clear and almost clear)

Secondary outcomes

  1. Number and percentage of cases responding to the treatment according to the IGA index score, analyzing the cases that received any topical or systemic treatment, comparing the baseline with the visits at 6 and 12 weeks

    Time frame: 12 weeks

    The treatments considered will be any topical or systemic treatment

  2. Number and percentage of cases responding to the treatment according to the IGA index score, analyzing the cases that received systemic treatment, comparing the baseline with the visits at 6 and 12 weeks

    Time frame: 12 weeks

    The treatments considered will be any systemic treatment

  3. Number and percentage of cases that need any treatment (topical or systemic) and number of days during the treatment period (12 weeks)

    Time frame: 12 weeks

    The number of treatment days and the number of participants prescribed treatment by the dermatologist will be counted

    The treatments considered will be any topical or systemic treatment

  4. Number and percentage of cases that need systemic treatment and number of days during the treatment period (12 weeks)

    Time frame: 12 weeks

    The number of treatment days and the number of participants prescribed systemic treatment by the dermatologist will be counted

    The treatments considered will be any systemic treatment

  5. Number and percentage of cases that need topical treatment and number of days during the treatment period (12 weeks)

    Time frame: 12 weeks

    The number of days and the number of participants prescribed topical treatment by the dermatologist will be counted

    The treatments considered will be any topical treatment

  6. Number and percentage of cases responding to the treatment according to the Dermatology Life Quality Index (DLQI) at 6 and 12 weeks

    Time frame: 12 weeks

    DLQI measures the impact rosacea has on your quality of life

    The index has 10 questions. Each question answered with "Very much" is counted with 3 points, "A lot" with 2, "Little" with 1, and "Not at all" as 0.

    The score obtained can range between 0 and 30 points, this being the worst possible score.

    It will be considered a treatment response in DLQI scale when the score is 0-5 points (no effect or mild effect in the quality of life)

  7. Number and percentage of cases responding to the treatment according to the IGA index score, comparing the baseline with the visit at 24 weeks (post-treatment follow-up)

    Time frame: 24 weeks

    IGA index measures the severity of rosacea

    Score range is from 0 to 6 according to the severity of the disease

    0=clear; 1=minimum; 2=mild; 3=mild-moderate; 4=moderate; 5=moderate-severe; 6=severe

    It will be considered a treatment response when the participant improves by at least 2 categories in this index and the final score is 0-1 points (clear and almost clear)

  8. Number and percentage of cases requiring any treatment (topical or systemic), along with the number of days, covering the total period (24 weeks) and the post-treatment follow-up period (from week 12 to 24)

    Time frame: 24 weeks

    The number of treatment days and the number of participants prescribed treatment by the dermatologist will be counted

    The treatments considered will be any topical or systemic treatment

  9. Number and percentage of cases requiring systemic treatment, along with the number of days, covering the total period (24 weeks) and the post-treatment follow-up period (from week 12 to 24)

    Time frame: 24 weeks

    The number of treatment days and the number of participants prescribed systemic treatment by the dermatologist will be counted

    The treatments considered will be any systemic treatment

  10. Number and percentage of cases requiring topical treatment, along with the number of days, covering the total period (24 weeks) and the post-treatment follow-up period (from week 12 to 24)

    Time frame: 24 weeks

    The number of treatment days and the number of participants prescribed topical treatment by the dermatologist will be counted

    The treatments considered will be any topical treatment

  11. Study treatment compliance rate at 6 and 12 weeks.

    Time frame: 12 weeks

    The treatment adherence is collected, checking the number of remaining capsules in each of the visits

Other outcomes

  1. Number of adverse events at 6 and 12 weeks

    Time frame: 12 weeks

    Adverse events reported by patients during follow-up at week 6 and week 12 visits are recorded

Sponsors and collaborators

Lead sponsor

Bionou Research, S.L.

Network

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of a Probiotic Mixture on the Evolution and Treatment of Rosacea

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Apr 18, 2023
Registry last updated
Sep 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.